OakChart

SOPHiA Genetics SA

SOPHHealthcare·Health Information Services·Switzerland·Small·NASD·Nov 11 • 3:59 PM ET

7.47-0.39 (-5.03%)
2026-11-12 02:09 CET
Market cap
669.10 USD m
Revenue, TTM
90.97 USD m
Net income, TTM
-81.13 USD m
Free cash flow, TTM
-45.11 USD m
EPS diluted, TTM
-1.09
P/E
-
Compare

Price

SOPH against its 20, 50 and 200-day averages
2050200missearnings
6.008.001.2M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SOPHclose 7.4720-day 7.2650-day 7.66200-day 6.027.4752w high

16.9% under the 52-week high of 8.98 on 27 Aug 2026. 52-week low 3.83 on 20 Nov 2025. Last 15 sessions, 35.1% high to low

Volume 1.32× normal · the line is the 50-bar volume average

Profile

SOPH
52-week range, 71% of the way up
3.838.98

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Employees415
IPOJul 23, 2021
Beta1.09
ATR, 14d0.53
Rel volume1.32
Short float1.86%
Insider own27.42%
Inst own42.13%

Snapshot

6 groups

Valuation

Index-
Market Cap635.47M
Enterprise Value602.86M
Income-81.13M
Sales90.97M
Book/sh0.80
Cash/sh1.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees415
IPOJul 23, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S6.99
P/B9.34
P/C6.79
P/FCF-
EV/EBITDA-
EV/Sales6.63
Quick Ratio2.16
Current Ratio2.29
Debt/Eq0.89
LT Debt/Eq0.85
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.09
EPS next Y-0.58
EPS next Q-0.17
EPS this Y18.63%
EPS next Y38.87%
EPS next 5Y30.31%
EPS past 3/5Y5.00% -13.68%
Sales past 3/5Y17.56% 22.16%
EPS Y/Y TTM2.08%
Sales Y/Y TTM24.11%
EPS Q/Q19.74%
Sales Q/Q24.69%
EarningsNov 03 BMO
EPS/Sales Surpr.-21.21% 0.98%

Ownership

Insider Own27.42%
Insider Trans-2.41%
Inst Own42.13%
Inst Trans8.43%
ROA-46.60%
ROE-125.67%
ROIC-63.99%
Gross Margin66.43%
Oper. Margin-79.88%
Profit Margin-89.18%
SMA202.76%
SMA50-2.56%
SMA20023.92%
Trades-

Technical

Shs Outstand85.66M
Shs Float61.78M
Short Float1.86%
Short Ratio1.81
Short Interest1.15M
52W High8.98 -16.87%
52W Low3.83 94.91%
Volatility7.01% 7.58%
ATR (14)0.53
RSI (14)50.85
Beta1.09
Rel Volume1.32
Avg Volume634.21K
Volume838,052

Performance

Perf Week7.10%
Perf Month5.29%
Perf Quarter-2.03%
Perf Half Y65.52%
Perf YTD59.85%
Perf Year61.58%
Perf 3Y119.56%
Perf 5Y-52.06%
Perf 10Y-
Recom1.00
Target Price10.25
Prev Close7.86
Price7.47
Change %-5.03%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Jul 20, 2026InitiatedHH.C. WainwrightBuy$12+60.8%
Dec 18, 2024InitiatedCCraig HallumBuy$11+47.4%
Aug 07, 2024DowngradeMMorgan StanleyOverweight → Equal-Weight$10 → $5-33.0%
Jun 27, 2024InitiatedGGuggenheimBuy$6-19.6%
Nov 29, 2023InitiatedRRBC Capital MktsOutperform$8+7.2%
Jul 05, 2023ResumedJJP MorganOverweight$10+34.0%
Jan 03, 2023InitiatedBBTIG ResearchBuy$6-19.6%
Nov 23, 2022InitiatedCCredit SuisseNeutral$2-73.2%
Oct 15, 2021ResumedCCowenOutperform
Aug 17, 2021InitiatedMMorgan StanleyOverweight$24+221.5%

Peers

Mkt cap
TickerCompanyMkt cap
TEMTempus AI Inc14.49B
ILMNIllumina Inc32.20B
QGENQiagen NV10.39B
CAICaris Life Sciences Inc7.02B
PSNLPersonalis Inc1.73B
FLGTFulgent Genetics Inc718.03M
WGSGeneDx Holdings Corp1.65B
VCYTVeracyte Inc2.03B
MYGNMyriad Genetics Inc548.68M
GHGuardant Health Inc20.94B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DAAN GUIDO MARIA VAN WELLOfficerNov 09 '26Proposed Sale7.141,41110,075Nov 09 04:34 PM
CARDOZA GEORGEChief Financial OfficerNov 06 '26Buy7.0620,000141,200326,726Nov 09 04:06 PM
Muken RossChief Executive OfficerNov 06 '26Buy6.8620,000137,188680,391Nov 09 04:05 PM
Menu PhilippeChief Medical OfficerOct 12 '26Sale7.265,00036,303195,993Oct 14 04:04 PM
Xu ZhenyuChief Scientific OfficerOct 13 '26Sale7.184,00028,727541,493Oct 14 04:03 PM
Camblong JurgiExecutive ChairmanOct 12 '26Sale7.268,50061,6713,387,150Oct 14 04:02 PM
Van Well DaanChief Legal OfficerOct 05 '26Sale8.126,16850,100332,716Oct 07 04:04 PM
Valente ManuelaChief People OfficerOct 05 '26Sale8.134,24034,487206,210Oct 07 04:04 PM
Verma AbhimanyuChief Technology OfficerOct 05 '26Sale8.125,28442,929166,887Oct 07 04:04 PM
Puylaert KevinChief Sales OfficerOct 05 '26Sale8.042161,737147,732Oct 07 04:04 PM
CARDOZA GEORGEChief Financial OfficerOct 05 '26Sale8.101,59212,897306,726Oct 07 04:04 PM
Menu PhilippeChief Medical OfficerOct 05 '26Sale8.137,39460,100200,993Oct 07 04:04 PM
Camblong JurgiExecutive ChairmanOct 05 '26Sale8.1340,172326,5263,395,650Oct 07 04:04 PM
Xu ZhenyuChief Scientific OfficerOct 05 '26Sale8.127,39460,075545,493Oct 07 04:04 PM

Held by

AUM
TickerCompanyAUM
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
MEDIHarbor Health Care ETFAUM: 44.19M
AIMSAcuitas Small Cap Active ETFAUM: 82.88M
GNMXCorgi Genomics & Precision Medicine ETFAUM: 1.28M

News

latest 14 of 200
  • SOPHiA GENETICS Misses On EPS As Dilution And Below-The-Line Costs Offset Revenue Beat And Sharply Narrower EBITDA Loss (Earnings Whispers)
  • SOPHiA GENETICS Reports Third Quarter 2026 Results (PR Newswire)
  • SOPHiA Genetics Must Prove Its US Surge Can Survive A Gross Margin Squeeze (Earnings Whispers)
  • SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026 (PR Newswire) +6.78%
  • SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology (PR Newswire)
  • SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics (Hospital Management) -7.89%
  • Sophia Genetics SA (SOPH) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.21%
  • SOPH Stock Heads For Best Day In Over 8 Months Whats Driving Todays Super Rally? (Stocktwits)
  • SOPHiA GENETICS Reports Second Quarter 2026 Results (PR Newswire)
  • SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies (PR Newswire)
  • SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 (PR Newswire)
  • SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting (PR Newswire)
  • SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
  • SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares (PR Newswire) +6.29%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.240-0.198-0.24024.2724.035
2026Q22026-08-04-0.300-0.210-0.30323.3121.725
2026Q12026-05-05-0.270-0.233-0.27221.6920.404
2025Q42026-03-03-0.280-0.238-0.28121.7120.494
2025Q32025-11-04-0.300-0.230-0.29519.4618.134
2025Q22025-08-05-0.330-0.214-0.33318.3217.495
2025Q12025-05-06-0.260-0.223-0.26017.7816.876
2024Q42025-03-04-0.230-0.205-0.22717.7317.716
2024Q32024-11-05-0.280-0.222-0.27815.8515.865
2024Q22024-08-06-0.230-0.266-0.23115.8117.405
2024Q12024-05-07-0.210-0.245-0.21015.7816.454
2023Q42024-03-05-0.370-0.218-0.36917.0517.334
2023Q32023-11-07-0.210-0.300-0.21216.3015.453
2023Q22023-08-08-0.330-0.294-0.33215.0515.245
2023Q12023-05-09-0.260-0.305-0.30713.9713.895
2022Q42023-03-07-0.170-0.342-0.21813.3812.925

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.130-1.337-1.15440.4540.89
2022FY-1.120-1.425-1.36447.5647.05
2023FY-1.220-0.993-1.22062.3762.49
2024FY-0.950-0.887-0.94665.1765.14
2025FY-1.170-1.118-1.17077.2776.20
2026FY--0.952--95.53
2027FY--0.582--118.98
2028FY--0.396--148.52
2029FY--0.067--195.2
2030FY-0.425--260.36

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0351126.2425.9426.60
2026Q4S2026-10-1850026.2925.9926.64
2026Q4S2026-10-0952126.2925.9926.64
2026Q4S2026-08-0452126.2926.0026.64
2026Q4S2026-07-1950026.1425.6626.94
2026Q4S2026-07-1750126.1425.6626.94
2026Q4S2026-06-1740126.2625.8026.94
2026Q4S2026-05-1740126.2625.8026.94
2026Q4S2026-05-0543126.2625.8026.94
2026Q4S2026-04-0944026.4626.0026.96
2026Q4S2026-03-0344026.4625.9926.96
2026Q4S2026-02-1341023.9923.1025.80
2026Q4S2026-01-2141023.9923.1025.80
2026Q4S2025-12-3141123.9923.1025.80

Estimate history

EPS, annual-0.529-0.616-1.154-1.364-1.22-0.946-1.17-1.0925
Period2019202020212022202320242025TTM
EPS, quarterly-0.278-0.227-0.26-0.333-0.295-0.281-0.272-0.303-0.237
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual25.36228.440.4547.5662.37165.17377.27190.97
Period2019202020212022202320242025TTM
Sales, quarterly15.85317.73317.77918.32319.46221.70721.68823.3124.267
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual63.85863.85863.85864.23165.23166.68768.48685.658
Period2019202020212022202320242025MRQ
Shares, quarterly66.43966.68766.82267.5867.84768.48671.7985.12885.658
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue90.9777.2765.1762.3747.5640.4528.4025.36
Cost of Goods Sold Incl. D&A30.5429.4626.3125.7020.7418.3612.999.45
Gross Profit60.4447.8138.8736.6826.8222.0915.4115.92
Selling, General and Administrative Excl. Other133.10118.74106.34113.59116.3195.2954.6048.64
Research and Development35.0233.5733.1335.6034.9227.1518.6214.84
Other Operating Expense0.000.000.000.000.000.00--
Operating Income-72.67-70.92-67.48-76.91-89.49-73.19-39.19-32.72
Interest Expense6.584.551.910.590.640.660.840.98
Unusual Expense5.223.82-0.370.000.071.47-0.610.10
Net Income Before Taxes-80.88-78.49-62.00-79.62-88.88-75.10-41.99-34.08
Income Taxes0.250.510.50-0.64-1.43-1.43-2.65-0.29
Consolidated Net Income-81.13-79.00-62.49-78.98-87.45-73.68-39.34-33.79
Net Income From Continuing Operations-81.13-79.00-62.49-78.98-87.45-73.68-39.34-33.79
Net Income-81.13-79.00-62.49-78.98-87.45-73.68-39.34-33.79
EPS (Recurring)-0.91-1.13-0.95-1.22-1.36-1.14-0.62-0.53
EPS (Basic, Before Extraordinaries)-1.09-1.17-0.95-1.22-1.36-1.15-0.62-0.53
EPS (Diluted)-1.09-1.17-0.95-1.22-1.36-1.15-0.62-0.53
EBITDA-61.74-61.40-58.88-68.57-83.92-69.58-36.80-30.80
Non-Operating Income (Expense)3.580.817.02-2.131.330.22-2.57-0.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.6612.8813.0312.5111.037.241.160.59
Price To Sales Ratio7.884.083.114.892.7822.26--
Gross Margin66.4361.8859.6358.8056.3854.6254.2762.76
Operating Margin-79.88-91.79-103.54-123.31-188.17-180.95-137.98-129.00
Net Margin-89.18-102.24-95.89-126.63-183.87-182.14-138.52-133.23
Shares Outstanding85.6668.4966.6965.2364.2363.8663.8663.86
Market Capitalization669.10669.10200.70306.30126.98900.39841.00-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue24.2723.3121.6921.7119.4618.3217.7817.73
Cost of Goods Sold Incl. D&A8.338.256.947.026.566.055.575.63
Gross Profit15.9315.0614.7514.6912.9112.2712.2112.10
Selling, General and Administrative Excl. Other33.2135.1232.0332.7430.1830.8328.2529.66
Research and Development8.308.739.468.548.078.499.129.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-17.27-20.06-17.28-18.05-17.27-18.56-16.04-17.56
Interest Expense1.621.621.671.671.660.560.660.03
Unusual Expense2.620.320.092.191.66-0.060.04-0.10
Net Income Before Taxes-19.96-22.28-19.07-19.57-19.38-21.65-16.88-14.54
Income Taxes0.310.080.25-0.400.640.760.500.62
Consolidated Net Income-20.27-22.36-19.32-19.18-20.02-22.41-17.39-15.16
Net Income From Continuing Operations-20.27-22.36-19.32-19.18-20.02-22.41-17.39-15.16
Net Income-20.27-22.36-19.32-19.18-20.02-22.41-17.39-15.16
EPS (Recurring)-0.22-0.30-0.27-0.26-0.28-0.33-0.26-0.23
EPS (Basic, Before Extraordinaries)-0.24-0.30-0.27-0.28-0.30-0.33-0.26-0.23
EPS (Diluted)-0.24-0.30-0.27-0.28-0.30-0.33-0.26-0.23
EBITDA-14.45-17.15-14.53-15.61-14.85-16.19-13.75-15.27
Non-Operating Income (Expense)1.56-0.28-0.032.331.22-2.59-0.142.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.903.852.843.083.303.463.034.01
Price To Sales Ratio7.884.944.344.124.402.993.303.14
Gross Margin65.6664.6168.0167.6866.3266.9768.6768.25
Operating Margin-71.19-86.05-79.69-83.15-88.76-101.28-90.24-99.02
Net Margin-83.54-95.91-89.09-88.35-102.87-122.33-97.78-85.48
Shares Outstanding85.6685.1371.7968.4967.8567.5866.8266.69
Market Capitalization669.10484.08354.76316.85321.68207.18221.88200.70

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments70.2980.23123.25178.61265.3297.3418.43
Short Term Receivables18.538.6915.218.057.097.859.71
Inventories6.355.876.485.165.733.383.61
Other Current Assets3.914.623.114.434.571.091.77
Total Current Assets99.0899.41148.05196.25282.70109.6833.52
Net Property, Plant & Equipment18.0519.3823.1021.4015.965.546.45
Total Investments and Advances1.980.000.000.000.000.000.00
Long-Term Note Receivable-----0.210.31
Intangible Assets35.8929.0027.1819.9615.6713.2810.24
Deferred Tax Assets2.252.871.721.941.992.110.00
Other Assets6.215.766.104.283.851.291.15
Total Assets163.46156.41206.16243.84320.17132.1251.66
Short Term Debt Incl. Current Port. of LT Debt2.702.192.932.691.813.913.19
Accounts Payable5.321.932.262.172.341.281.73
Other Current Liabilities42.5122.6830.4421.9524.4516.4014.34
Total Current Liabilities50.5326.8035.6226.8128.6021.5919.26
Long Term Debt60.3227.8415.6714.0511.253.345.27
Provision for Risks Charges4.163.843.092.674.765.464.23
Deferred Tax Liabilities0.421.10-----
Other Liabilities0.880.340.330.170.161.220.64
Total Liabilities116.3159.9254.7143.7144.7731.6129.40
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity47.1596.49151.44200.13275.40100.5122.25
Total Shareholders Equity47.1596.49151.44200.13275.40100.5122.25
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity47.1596.49151.44200.13275.40100.5122.25
Total Liabilities & Stockholders Equity163.46156.41206.16243.84320.17132.1251.66
Book Value Per Share0.691.452.323.124.311.570.35
Tangible Book Value Per Share0.161.011.902.804.071.370.19
Full-Time Employees415423449466518--
Price to Book Ratio9.841.801.940.643.272.90-
Return on Assets-49.40-34.47-35.10-31.01-32.58-42.81-
Return on Equity-110.00-50.41-44.93-36.78-39.20-64.09-
Return on Invested Capital-73.51-50.26-47.26-40.83-25.70-37.88-122.76
Quick Ratio1.843.493.977.139.684.921.55
Current Ratio1.963.714.167.329.885.081.74

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-79.70-77.49-61.27-78.50-87.59-73.51-41.23-33.63
Depreciation10.769.538.608.345.573.612.391.91
Other Funds (Non Cash)18.0619.2412.4320.7113.195.843.291.66
Funds from Operations-50.88-48.72-40.24-49.45-68.82-64.06-35.55-30.06
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital6.8510.71-2.580.87-1.276.123.82-1.62
Cash from Operating Activities-44.03-38.01-42.82-48.58-70.09-57.94-31.73-31.68
Capital Expenditures-10.21-8.62-8.18-9.23-10.38-6.67-3.20-3.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-1.44-1.890.0017.5552.35-50.26-21.120.00
Purchase of Investments-1.44-1.890.000.00-26.18-72.14-21.120.00
Sale Or Maturity of Investments0.000.000.0017.5578.5321.880.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-11.65-10.51-8.188.3241.97-56.93-24.32-3.03
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock71.141.440.410.230.75244.33108.721.76
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock71.141.440.410.230.75244.33108.721.76
Proceedsfrom Stock Options68.841.090.000.000.00239.80107.640.00
Issuance or Reduction of Debt, Net-34.5613.930.000.00-3.17-0.69-1.97
Change in Long Term Debt---0.00----
Issuance of Long Term Debt---0.00----
Reduction of Long Term Debt---0.00----
Net Financing Active Other Cash Flow0.000.000.000.000.00-2.470.000.00
Other Financing Activities Uses0.000.000.000.000.00-2.470.000.00
Cash from Financing Activities68.4634.1311.59-2.82-1.57237.77107.05-1.02
Exchange Rate Effect-1.684.45-3.615.02-1.97-4.565.56-0.10
Net Change in Cash11.10-9.94-43.03-38.05-31.66118.3456.56-35.84
Free Cash Flow-45.11-38.59-43.07-50.07-74.19-60.62-32.18-33.03
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments93.65107.6765.3970.2981.6194.82
Short Term Receivables16.7314.1114.3118.538.469.51
Inventories7.167.087.096.356.686.22
Other Current Assets8.098.439.023.916.746.49
Total Current Assets125.63137.2995.8199.08103.48117.03
Net Property, Plant & Equipment14.5215.9416.8018.0517.6218.47
Total Investments and Advances0.000.000.001.980.000.00
Intangible Assets35.8536.1635.8235.8934.6833.73
Deferred Tax Assets1.641.771.812.251.671.75
Other Assets7.107.206.756.216.016.63
Total Assets184.73198.36157.00163.46163.46177.62
Short Term Debt Incl. Current Port. of LT Debt2.692.722.712.702.612.48
Accounts Payable10.2811.9012.678.966.067.73
Other Current Liabilities41.9536.4631.2138.8728.2624.27
Total Current Liabilities54.9251.0846.5950.5336.9334.48
Long Term Debt58.3559.1159.7160.3260.7661.33
Provision for Risks Charges1.753.824.104.164.414.49
Deferred Tax Liabilities---0.42--
Other Liabilities1.281.230.900.880.670.63
Total Liabilities116.30115.24111.31116.31102.77100.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity68.4383.1245.6947.1560.6976.69
Total Shareholders Equity68.4383.1245.6947.1560.6976.69
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity68.4383.1245.6947.1560.6976.69
Total Liabilities & Stockholders Equity184.73198.36157.00163.46163.46177.62
Book Value Per Share0.800.980.640.690.891.13
Tangible Book Value Per Share0.380.550.140.160.380.64
Full-Time Employees---415--
Price to Book Ratio9.849.077.195.224.192.42
Return on Assets-46.60-43.02-53.30-49.40-43.97-40.92
Return on Equity-125.67-101.22-123.28-110.00-86.09-74.09
Return on Invested Capital-15.99-15.72-18.33-17.85-16.48-16.24
Quick Ratio2.162.551.901.842.623.21
Current Ratio2.292.692.061.962.803.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.88-22.09-19.07-19.65-20.69-23.30
Depreciation2.682.882.752.452.592.57
Other Funds (Non Cash)5.715.703.623.034.737.72
Funds from Operations-10.49-13.52-12.70-14.17-13.37-13.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.304.80-3.485.242.963.72
Cash from Operating Activities-10.20-8.72-16.18-8.94-10.41-9.29
Capital Expenditures-2.18-2.67-2.87-2.49-2.85-2.12
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.00-1.44-0.520.00
Purchase of Investments0.000.000.00-1.44-0.520.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.18-2.67-2.87-3.93-3.37-2.12
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.7855.6714.961.290.090.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.7855.6714.961.290.090.08
Proceedsfrom Stock Options-1.7169.410.001.140.000.00
Issuance or Reduction of Debt, Net0.000.000.00-0.410.29-
Change in Long Term Debt-0.000.00---
Issuance of Long Term Debt-0.000.00---
Reduction of Long Term Debt-0.000.00---
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-1.3755.0514.390.40-0.1635.65
Exchange Rate Effect-0.58-1.55-0.240.690.182.67
Net Change in Cash-14.3342.11-4.90-11.78-13.7626.92
Free Cash Flow-9.91-8.86-17.06-9.28-10.52-9.42

Revenue breakdown

Asia Pacific2024: 4.05M 2025: 5.21M
France2024: 10.33M 2025: 11.32M
Italy2024: 9.98M 2025: 10.81M
Latin America2024: 2.89M 2025: 3.09M
Other Countries In Europe, Middle East, And Africa2024: 19.33M 2025: 25.65M
Other Countries In North America2024: 1.98M 2025: 2.53M
Spain2024: 5.79M 2025: 6.03M
Switzerland2024: 1.49M 2025: 1.78M
United States2024: 9.32M 2025: 10.87M
SOPHiA DDM Platform2024: 63.55M 2025: 74.92M
Workflow Equipment And Services2024: 1.63M 2025: 2.36M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.86%1.1M61.8M598.25K
2026-10-151.62%1.0M61.8M576.66K
2026-09-301.83%1.1M61.3M515.46K
2026-09-151.74%1.1M61.3M479.17K
2026-08-311.80%1.1M61.3M394.99K
2026-08-141.54%0.9M60.4M308.12K
2026-07-311.28%0.8M59.8M237.81K
2026-07-151.11%0.7M59.8M201.28K
2026-06-301.13%0.6M56.3M162.84K
2026-06-150.55%0.3M48.2M104.11K
2026-05-290.58%0.3M48.1M101.06K
2026-05-150.49%0.2M48.2M106.03K
2026-04-300.41%0.2M48.1M128.39K
2026-04-150.37%0.2M48.1M189.01K
2026-03-310.45%0.3M56.2M196.40K
2026-03-130.38%0.2M56.2M185.63K
2026-02-270.34%0.2M53.2M180.13K
2026-02-130.42%0.2M53.2M181.58K
2026-01-300.14%0.1M53.1M156.65K
2026-01-150.10%0.1M53.1M108.92K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.606.100.0012.1370.000.000.978-0.0150.001
call5.002.153.601.755.79310.000.000.947-0.0130.001
call7.500.001.150.752.51712.000.000.555-0.0500.005
call10.000.000.950.053.6873.000.000.413-0.0950.005
call12.500.001.000.082.22313.000.000.095-0.0250.002
call15.000.001.000.002.7670.000.000.081-0.0270.002
put2.500.001.000.004.1590.000.00-0.022-0.0140.001
put5.000.001.000.111.74313.000.00-0.053-0.0120.001
put7.500.000.600.891.2704.000.00-0.445-0.0490.005
put10.001.553.100.002.8460.000.00-0.587-0.0940.005
put12.504.005.700.004.0280.000.00-0.905-0.0230.002
put15.006.508.200.004.7200.000.00-0.919-0.0260.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11278.39K200
2026-1000795.52K12
2026-0900243.94K7
2026-08001.22M19
2026-0700810.66K15
2026-0699.00K1966.34K11
2026-0500179.37K12
2026-0400926.08K51
2026-030041.87K9
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GENERATION INVESTMENT MANAGEMENT LLP8.09%
ROYCE & ASSOCIATES LP4.57%
AKRE CAPITAL MANAGEMENT LLC4.43%
AMERIPRISE FINANCIAL INC2.64%
BANQUE PICTET & CIE SA2.59%
PRINCIPAL FINANCIAL GROUP INC2.53%
AWM Investment Company, Inc.2.03%
AIGH Capital Management LLC1.98%
Soleus Capital Management, L.P.1.87%
SILVERCREST ASSET MANAGEMENT GROUP LLC1.70%

Funds

Fund% owned
Columbia Small Cap Growth Fund2.56%
SmallCap Fund1.28%
ROYCE MICRO-CAP TRUST, INC.1.05%
Royce Small-Cap Opportunity Fund0.79%
Royce Micro-Cap Fund0.44%
ROYCE SMALL-CAP TRUST, INC.0.35%
Royce Small-Cap Fund0.30%
1290 Essex Small Cap Growth Fund0.19%
Royce Capital Fund - Micro-Cap Portfolio0.15%
SmallCap Account0.11%

OakChart. SOPH. Cached 15 minutes.